RSS XORTX Appoints Michael Bumby As CFO, Replacing James Fairbairn

Currently reading:
 RSS XORTX Appoints Michael Bumby As CFO, Replacing James Fairbairn

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,205
Likes
1,915
Credits
32,754©
Cash
0$
XORTX Therapeutics Inc. (XRTX), a pharmaceutical company focusing on late-stage clinical developments, has announced the appointment of Michael Bumby as their new Chief Financial Officer. Bumby, a seasoned professional in the biotech and pharmaceutical industry, will be succeeding James Fairbairn. Currently serving as the director and audit committee chair at MediPharm Labs, following its acquisition of VIVO Cannabis Inc., Bumby also previously held the position of CFO at VIVO Cannabis for six years. His extensive career includes a notable 14-year tenure at the prominent pharmaceutical company, Eli Lilly.

Chairman Anthony Giovinazzo expressed confidence in Bumby’s capabilities, emphasizing that his combined expertise in science and finance, along with his vast experience in business and drug development, will be instrumental in helping XORTX achieve its immediate and future goals.

On Wednesday, XRTX's stock concluded regular trading on the Nasdaq with a 4.27% increase, closing at $1.12.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips
Top Bottom